Currently available hypolipidaemic drugs and future therapeutic developments
Authors:
- Antonio M. GottoAGAntonio M. Gotto
- 1 October 1995
- journal article
- Published by Elsevier in Bailliere's Clinical Endocrinology and Metabolism
- Vol. 9 (4) , 825-847
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Atorvastatin: a step ahead for HMG-CoA reductase inhibitorsAtherosclerosis, 1994
- Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS)Annals of Internal Medicine, 1993
- Hemorheologic and Coagulative Pattern in Hypercholesterolemic Subjects Treated with Lipid-Lowering DrugsAngiology, 1991
- Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein BNew England Journal of Medicine, 1990
- LovastatinArchives of internal medicine (1960), 1990
- Influence of probucol administration on lipoprotein cholesterol and apolipoproteins in normolipemic malesAtherosclerosis, 1988
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- Prolongation of the QT interval induced by probucol: Demonstration of a method for determining QT interval change induced by a drugAmerican Heart Journal, 1984
- Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.Circulation, 1984
- Digitalis intoxication. Treatment with a new steroid-binding resin1972